International Journal of Infectious Diseases
Volume 13, Issue 6 , Pages e467-e469 , November 2009

Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients—a report of two cases

Received 20 July 2008 ,Revised 25 November 2008 ,Accepted 15 December 2008.

References 

  1. Patel N, Koziel H. Pneumocystis jirovecii pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med. 2004;3:381–397
  2. Thomas C, Limper A. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–2498
  3. Curtis JR, Yarnold PR, Schwartz DN, Weinstein RA, Bennett CL. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2000;162:393
  4. Gordin F, Simon G, Wofsy C, Mills J. Adverse reactions to trimethoprim–sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495–499
  5. Smilack JD. Trimethoprim–sulfamethoxazole. Mayo Clin Proc. 1999;74:730–734
  6. Klein NC, Duncanson FP, Lenox TH, Forszpaniak C, Sherer CB, Quentzel H, et al. Trimethoprim–sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6:301
  7. Hughes WT, LaFon SW, Scott JD, Masur H. Trimethoprim–sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986;105:37
  8. Hughes W, LaFon S, Scott J, Masur H. Adverse events associated with trimethoprim–sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis. 1995;171:1295–1301
  9. Altraif I, Lilly L, Wanless I, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim–sulfamethoxazole. Am J Gastroenterol. 1994;89:1230–1234
  10. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology. 1992;102:2148–2150
  11. Brett AS, Shaw SV. Simultaneous pancreatitis and hepatitis associated with trimethoprim–sulfamethoxazole. Am J Gastroenterol. 1999;94:267–268
  12. Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother. 2003;37:1810–1813
  13. Versleijen MW, Naber AH, Riksen NP, Wanten GJ, Debruyne FM. Recurrent pancreatitis after trimethoprim–sulfamethoxazole rechallenge. Neth J Med. 2005;63:275–277
  14. Yao F, Behling C, Saab S, Li S, Hart M, Lyche K. Trimethoprim–sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol. 1997;92:167–169
  15. Takahashi T, Taguchi H, Nakamura T, Yoshikawa K, Iwamoto A. Focal hepatic lesions on magnetic resonance imaging induced by trimethoprim/sulfamethoxazole in HIV infection. Ann Pharmacother. 1999;33:1007–1008
  16. Merkel IS, Good CB, Nalesnik M, Roseman SR. Chronic Pneumocystis carinii infection of the liver. A case report and review of the literature. J Clin Gastroenterol. 1992;15:55–58
  17. Sachs JR, Greenfield SM, Sohn M, Turner JL. Disseminated Pneumocystis carinii infection with hepatic involvement in a patient with the acquired immune deficiency syndrome. Am J Gastroenterol. 1991;86:82–85

PII: S1201-9712(09)00068-X

doi: 10.1016/j.ijid.2008.12.016

International Journal of Infectious Diseases
Volume 13, Issue 6 , Pages e467-e469 , November 2009

Article Tools

* Image Usage & Resolution